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Selective androgen receptor modulators (SARMs) represent an emerging class of drugs likely to 
be abused in sport. For clinical applications, these substances provide a promising alternative to 
testosterone-replacement therapies and their advantages include oral bioavailability, androgen 
receptor specificity, tissue selectivity, and the absence of steroid-related side effects. Although not 
yet commercially available, since January 2008 SARMs have been included on the prohibited list 
issued yearly by the World Anti-Doping Agency (WADA), so control laboratories need to update 
their procedures to detect either the parent drugs or their metabolites. Within this context, two 
quinolinone SARM models were synthesized and automatically characterized to update the 
existing routine screening procedures. The conditions for the new target analytes are compatible 
with the existing laboratory protocols used for both incompetition and out-of-competition controls 
and can be included in them. Validation parameters according to ISO 17025 and WADA guidelines 
were successfully determined. For analytical determinations, spiked urine samples were 
hydrolyzed and extracted at pH 9.6 with 10 mL of tert-butyl methyl ether. Then, the analytes were 
subsequently converted into trimethylsilyl derivatives and detected by gas chromatography–mass 
spectrometry. The absence of interferents, together with excellent repeatability of both retention 
times and the relative abundances of diagnostic ions, allowed proper identification of all SARM 
analytes. The analytes’ quantification was linear up to 500 ng/mL and precision criteria were 
satisfied (coefficient of variation less than 25% at 10 ng/mL). The limits of detection were 1 ng/mL 
for both SARMs, whereas recovery values were between 95.5 and 99.3%. The validated method 
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Endogenous androgens are essential for male development, spermatogenesis, and the 
maintenance of male secondary characteristics, such as bone mass, muscle mass, and body 
composition [1]. In recent years, testosterone has been used to treat hypogonadism, muscle 
wasting, osteoporosis, cancer cachexia, anemia, age-related frailty, for male contraception, and as 
hormone-replacement therapy in aging men [2–5]. The limited oral bioavailability of testosterone as 
well as the need to differentiate desired anabolic from undesired androgenic effects led to the 
synthesis, and clinical testing, of numerous derivatives of anabolic androgenic steroids such as 
nandrolone decanoate and stanozolol that have been shown to increase bone mass by stimulation 
of bone formation [6, 7]. However, serious side effects associated with steroid-replacement 
therapies, including hepatic toxicity, decreased levels of HDL cholesterol, gynecomastia, and 
prostatic and cardiovascular illness [8–10], have driven research toward drugs with different 
mechanisms of action. From this research, selective androgen receptor modulators (SARMs) 
emerged as a new class of promising drugs. SARMs represent a novel class of drugs for the 
treatment of various debilitating diseases, muscle wasting, osteoporosis, and for male 
contraception [11–17]. Major advantages of these drugs are the tissue-selective anabolic 
properties combined with considerably reduced side effects commonly associated with steroid-
replacement therapies [18]. In fact, the metabolism of these drugs does not involve the enzymatic 
activities that are responsible for testosterone metabolism and, in particular, its transformation  by 
aromatase and 5α-reductase enzymes [14, 19]. A series of orally bioavailable SARMs with various 
chemical structures were prepared and submitted to advanced clinical trials [20–22] as well as 
metabolic and spectrometric studies [23–28]. Currently investigated SARMs can be categorized by 
their common core structures into five classes: arylpropionamide, bicyclic hydantoins, quinolines, 
tetrahydroquinolines, and 4-azasteroids. Owing to their properties, SARMs are likely to be 
attractive to athletes, as these drugs offer the anabolic effects without the androgenic effects which 
are commonly associated with traditional anabolic androgenic steroid misuse. Although these 
drugs are not clinically approved yet, the availability of these substances on the black market was 
recently recognized [29]. On the basis of these facts, SARMs were added to the prohibited list 
issued annually by the World Anti-Doping Agency (WADA) since January 2008 [30]. Therefore, in 
recent years, several doping control analytical assays have been developed for arylpropionamide-, 
hydantoin-, quinoline-, and tetrahydroquinoline-derived SARMs [31–37] to establish new screening 
and confirmation procedures or to update existing assays with these target compounds. Moreover, 
additional in vivo and in vitro metabolism experiments were conducted and the detection of major 
metabolites was implemented in existing sport drug testing [25, 38, 39]. Although several methods 
for the detection of SARMs employing liquid chromatography–tandem mass spectrometry (MS) 
techniques were recently described, the analysis of this class of substances using conventional 
gas chromatography (GC)/MS approaches would be a useful complementary method as GC/MS 
systems are still an extensively employed tool in sport drug testing [40]. In the present work, two 
quinolinone-derived SARMs that possess tissue-selective androgen receptor agonist activity [41, 
42], and not commercially available, were chemically synthesized (Fig. 1), and their 
massspectrometric behavior under electron ionization (EI) was studied. A procedure to detect 
these compounds in spiked urine specimens using GC/EI-MS employing selected ion monitoring 
(SIM) was developed and validated according to existing guidelines. Although the metabolism of 
these SARMs has not been described in the scientific literature yet, an in vitro metabolism study is 




Chemicals and reagents 
 
17α-Methyltestosterone, methanol, tert-butyl methyl ether (TBME), β-glucuronidase (from 
Escherichia coli), dithioerythritol, ammonium iodide (NH4I), sodium hydrogen carbonate 
(NaHCO3), sodium carbonate (Na2CO3), sodium phosphate dibasic dehydrate (Na2HPO4·2H2O), 
and potassium phosphate monobasic (KH2PO4) were from Sigma-Aldrich (Milan, Italy). N-Methyl-
N-trimethylsilyltrifluoroacetamide (MSTFA) was obtained from Merck (Darmstadt, Germany). All 
solution and buffers were prepared using deionized water obtained from a Milli-Q system (Millipore, 
Billerica, USA). Phosphate buffer (0.1 M) was prepared by dissolving 4.63 g of KH2PO4 and 11.75 
g of Na2HPO4·2 H2O in 1 L of water, whereas carbonate buffer was prepared by dissolving 2.12 g 
of Na2CO3 and 6.72 g of NaHCO3 in 1 L of water. 
 
Synthesis and characterization of model compounds 
 
Quinolinone-derived SARMs were prepared as described elsewhere according to established 
procedures [44, 45]. Target compounds were characterized by high-resolution/high-accuracy MS 
using an LTQ Orbitrap (Thermo, Bremen, Germany) employing an electrospray ionization source 
operating in positive mode, and nuclear magnetic resonance (NMR) spectroscopy with 1H, 
distortionless enhancement by polarization transfer, and 13C experiments employing a Bruker 
Avance 300 instrument (Bruker, Karlsruhe, Germany). 
 
Stock and working solution 
 
Stock standard solution were prepared in methanol at a concentration of 1,000 μg/mL and were 
stored at -20 °C until used. Working solutions were prepared at 10 μg/mL by dilution with methanol. 
Gas chromatography/electron ionization–mass spectrometry GC/MS determinations were 
performed using a 6890N gas chromatograph (Agilent Technologies, Milan, Italy) equipped with a 
17-m fused-silica capillary column (J&W Scientific HP-1), of 0.2-mm inner diameter and 0.11-μm 
film thickness, for GC separation. Helium was employed as the carrier gas at a constant pressure 
of 20.16 psi. The gas chromatograph oven temperature was set at 120 °C for 3 min and then 
raised to 315 °C with a 15 °C/min heating rate. The total run time was 16 min. The gas 
chromatograph injector and transfer line were maintained at 280 °C. Fragmentation patterns of 
trimethylsilyl derivatives were investigated using a 5975 inert mass-selective detector (Agilent 
Technologies, Milan, Italy) with EI at 70 eV. Three diagnostic ions of each analyte were chosen 




The sample preparation involved minor modifications from the standard operating procedure 
described by Donike et al. [46] for the detection of anabolic steroids. Urine samples (3 mL) were 
fortified with 150 ng of the internal standard (ISTD) 17α-methyltestosterone, and then were 
buffered to pH 7.4 with 2 mL of a 0.1 M phosphate buffer. β-Glucuronidase (30 μL) was 
subsequently added and the mixture was incubated at 55 °C for 1 h. Once the hydrolysis was 
complete, the mixtures were cooled to room temperature and 2 mL of 0.1 M carbonate buffer was 
added to raise the pH to 9.6. Liquid–liquid extraction was performed by adding 10 mL of TBME and 
shaking the mixture in a multimixer for 10 min. After centrifugation at 2,200 rpm for 3 min, the 
organic layer was transferred into a vial and dried under nitrogen at 70 °C. The dry residue was 
derivatized with 50 μL of an MSTFA/ NH4I/dithioerythritol (1,000:2:4, v/w/w) solution for 30 min at 




Method validation was performed according to ISO 17025 requirements and WADA and ICH 
guidelines [47, 48]. Therefore, the qualitative determination of the 2-quinolinone-derived SARMs in 
human urine was validated for linearity, specificity, limit of detection (LOD), precision, and 
recovery. Blank urine specimens required for the method validation were obtained from ten 




Ten different blank urine samples were prepared as described already. The occurrence of possible 
interferences from endogenous substances or derivatization byproducts was tested by monitoring 
the selected-ion chromatograms, characteristic for each compound investigated, at the retention 




The linear calibration model was checked by analyzing blank urine samples spiked with standard 
solutions at concentrations of 5, 10, 25, 50, 100, 250, and 500 ng of each analyte per milliliter of 
urine. 17α-Methyltestosterone at a final concentration of 50 ng/mL was used as the ISTD. The 
linear calibration parameters were obtained using the least-squares regression method, whereas 
the correlation coefficient (R2) was utilized to estimate linearity. Quantitative results from area 
counts were corrected using the ISTD signal. 
 
Limit of detection 
 
LODs were estimated as the analyte concentrations whose response provided a signal-to-noise 
(S/N) ratio of 3, as determined from the least abundant qualifier ions. The S/N ratios at the lowest 
concentration were used to extrapolate the theoretical LOD. These calculated LODs were then 





The recovery of each compound was determined at 10, 100, and 500 ng/mL. Mean extraction 
recovery values were obtained by comparing two experimental sets of data. In the first set, ten 
blank urine samples were spiked before the extraction step with target compounds, whereas in the 
second set, ten blank urine samples were spiked after the extraction step, with standard working 
solutions, at the same final concentration. For both sets of samples, the TBME layer was spiked 
with 150 ng of ISTD before evaporation. Recovery (%) was calculated as the ratio between the 
response (analyte peak area/ISTD peak area) obtained from the two separate series of samples. 




Intraday precision, expressed as percent coefficient of variation (CV%), was assessed by 
extracting and analyzing, within 1 day, ten replicates of blank urine samples, spiked with the 
standard solutions at three concentrations (final concentrations of 10, 100, and 500 ng/mL for each 
analyte), performed by the same operator.  
Interday precision 
 
On three consecutive days, ten urine samples with low (10 ng/mL), medium (100 ng/mL), and high 
(500 ng/mL) concentrations of target compounds were prepared and analyzed by the same 
operator. Interday precision, expressed as CV%, was calculated for each concentration. The 
interday/intraday precision was considered satisfactory when the CV% values were below 15% at 
high concentrations and below 25% at low concentration. 
 
Results and discussion 
 
Synthesis and characterization of model compounds The syntheses provided sufficient amounts of 
the desired structures as pure analytes necessary for method development and structural 
characterization; the purities were greater than 95% in all cases. Accurate mass measurement 
allowed the determination of the elemental composition of protonated molecules: compound 1 
elemental composition C14H11O2N2F6, m/z (theoretical) 353.0719, m/z (experimental) 353.0725, 
error 1.7 ppm; compound 2 elemental composition C15H16ON2F3, m/z (theoretical) 297.1209, m/z 
(experimental) 297.1215, error 2.0 ppm. Model SARMs were characterized by NMR analyses. 
Compound 1: 1H NMR [300 MHz, dimethyl-d6 sulfoxide (d6-DMSO)] δ 11.98 (br s, 1H, NH), 6.92 
(s, 1H, 8-H), 6.84, 6.74 (2 s, 2×1H, 5-H and 10-H), 4.28 (t, 2H, J=4.2 Hz, 3-H), 4.20 (q, 2H, J=9.6 
Hz,CH2CF3), 3.52 (t, 2 H, J=4.2 Hz, 2-H). 13C NMR (75 MHz, d6-DMSO) δ 159.8, 148.1, 136.0 (q, 
J=30.4 Hz), 134.1, 130.7, 125.6 (q, J=281.1 Hz), 122.6 (q, J=273.2 Hz), 118.4 (q, J=4.7 Hz), 107.9, 
105.5, 102.8, 64.6, 51.9 (q, J=32.1 Hz), 47.8.  
Compound 2: 1H NMR (300 MHz, CD3OD) δ 7.30 (s, 1 H, 5-H), 6.46 (s, 1H, 7-H), 6.37 (s, 1H, 10-
H), 3.31 (m, 2H, 2-H), 2.69 (m, 1H, 4-H), 1.86 (m, 2 H, 3-H), 1.60 (m, 2H, CH2CH3), 0.99 (t, 3H, 
CH2CH3). 13C NMR (75 MHz, CD3OD/d6-DMSO 1:1) δ 163.0, 149.4, 141.2, 138.9 (q, J=30,6 Hz), 
124.9, 123.9 (q, J=275.6 Hz), 123.4, 112.7 (q, J=5.6 Hz), 104.9, 96.9, 38.2, 37.8, 28.8, 25.5, 11.5. 
 
Interpretation of electron ionization mass spectra 
 
A comprehensive assignment of the ultimate structures to EI mass fragments is beyond the scope 
of this study. However, a highly liable interpretation of EI mass spectra is made possible by 
comparison with definitive studies on homologue SARMs [26, 33]. The mass spectrum of the 
trimethylsilyl derivative of 1 (Fig. 2) shows a molecular ion at m/z 424. The base peak at m/z 409 is 
generated by the loss of a methyl radical (-15 u) from the trimethylsilyl residue. The subsequent 
elimination of trifluoroethane (-84 u) leads to a fragment ion at m/z 325. The release of a 
trifluoromethyl radical (-69 u) from the molecular ion produces the fragment ion at m/z 355. 
According to previous studies on 2-quinolinone-derived SARMs [26, 32, 33], the trifluoromethyl 
radical located on the aromatic ring is identified as the leaving group and cleavage of the cyclic 
structure was suggested. The subsequent loss of trifluoroethane (-84 u) or acetaldehyde (-44 u) 
possibly yields the fragment ion at m/z 271 or m/z 311, respectively. Trimethylsilylation of 2 yielded 
a structure with a molecular mass of 440 u. Under EI conditions, the molecular ion decomposes to 
products ions at m/z 425, 395, 351, 411, and 337 (Fig. 3). The first three fragments most likely 
arise from loss of a methyl radical (-15 u) followed by the elimination of ethane (-30 u) or 
trimethylsilane (-74 u), giving the fragments at m/z 395 and m/z 351, respectively. The fragment at 
m/z 411 reasonably results from the loss of an ethyl radical (-29 u) from the molecular ion, whereas 
a consecutive elimination of a trimethylsilane molecule (-74 u) could be hypothesized to justify the 




On the basis of the mass-spectrometric data, three diagnostic ions of each analyte were chosen 
and acquired for qualitative analyses according to WADA guidelines: compound 1m/z 409, 424, 
and 355 (Fig. 2); compound 2m/z 440, 425, 411 (Fig. 3); ISTD m/z 301, 446, and 431. A SIM-
GC/MS chromatogram obtained from a blank urine specimen fortified with 5 ng/mL of each 




Evaluating ten blank urines for endogenous interferences, we observed no quantifiable analyte 
peaks (i.e., S/N ratio less than 3) at the expected retention time. This demonstrated that the 
method is selective for the compounds tested and is free from positive interference from urine 




The range of concentration studied was planned according to the approximate response factors 
obtained from the preliminary experiments with standard solutions. The calibration plots show good 
linearity for both SARMs under study in the interval 5–500 ng/mL. The coefficient of correlation 






Limit of detection 
 
LODs for both compounds were estimated from calculation  (see “Experimental”) at 1 ng/mL (Table 
1). Estimated LODs were experimentally confirmed by analyzing in triplicate a blank urine sample 
spiked with the target analytes at the LOD concentrations. All S/N ratios observed exceeded the 
critical value of 3, as expected. For this class of substances, the WADA requirements do not 
establish a limit for the minimum required performance, whereas for anabolic agents the fixed 
minimum required performance is 10 ng/mL [49]. Therefore, the LOD of 1 ng/mL measured for 
these SARMs appears satisfactory in comparison with what is required for anabolic steroids or 




Recovery values are reported in Table 1. The recoveries of compounds 1 and 2 were 101.2 and 
99.5%, respectively, for the low level, 99.3 and 95.5% for the medium level, and 96.7 and 96.6% 
for the high level. These high recovery values, obtained by applying a well-established extraction 
procedure for anabolic steroids, clearly indicate that the new target analytes could be directly 
included in existing drug screening procedures.  
 
Intraday and interday precision 
 
The retention time and the relative abundances of the characteristic ions were respected for all 
tests. Repeatability of the retention times was excellent, with CV% values below 0.1% for the 
analytes at 10, 100, and 500 ng/mL and for the ISTD at 50 ng/mL. Repeatability of the relative 
abundances for the characteristic ions was satisfactory. At the three concentrations tested, for 
compound 1, CV% values were below 5% for all ions monitored, whereas for compound 2 and 
ISTD, CV% values were below 2.5% for all ions monitored. The values obtained show a 
satisfactory intraday precision represented by CV% lower than 15% for the samples spiked at 10 
and 100 ng/mL and 10% for the samples spiked at 500 ng/mL (Table 1). The interday precision of 
the method, expressed as CV%, was lower than 20% for the samples spiked at 10 and 100 ng/mL 
and 15% for the samples spiked at 500 ng/mL (Table 1). According to standard criteria taken from 
the literature that designate satisfactory intra-assay precision for qualitative screening methods 
when CV% values are below 15% at high concentrations and below 25% at lower concentrations 






In sport doping, the misuse of new drugs often anticipates the completion of their clinical trials and 
their industrial production and marketing. This is the case for several SARMs, whose 
administration induces anabolic/androgenic effects without the occurrence of most side effects 
typical of anabolic androgenic steroids. For this reason, it is necessary to continuously update the 
analytical procedures devoted to doping control, to include the new drugs as soon as they become 
available. In this study two model compounds representing quinolinone-based SARMs were 
synthesized and included in a validated GC/MS method to provide chromatographic and mass-
spectral data useful to doping control laboratories. The analysis of these drugs in urine samples for 
antidoping purposes has never been published before. Future studies, including in vitro 
metabolism experiments, will provide further awareness about potential metabolic products to 
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CV (%) CV (%) 
1 1 10 101.2 14.8 10.6 
  100 99.3 10.1 14.2 
  500 96.7 9.4 10.1 
2 1 10 99.5 12.2 16.2 
  100 95.5 8.7 15.1 
  500 96.6 8.1 9.5 
a 
Concentration levels for recovery and precision determination 
























































































































Fig. 4 GC/MS-SIM chromatogram of a blank urine fortified with the target compounds at the concentration 
of 5 ng/mL 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
